Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities
Yaw Adu(Texas Tech University), Sikander Ailawadhi(Jacksonville College), Ahsan Rasheed(WinnMed), Saurav Das(Griffin Hospital), Vivek Roy(Jacksonville College), Dhaani Ailawadhi(Jacksonville University), Andre Fernandez(Mayo Clinic in Florida), Sean M. O’Connell(Mayo Clinic in Florida), Taimur Sher(Mayo Clinic in Florida), Asher A Chanan Khan(WinnMed), Ricardo Parrondo(Jacksonville College)
Cited by 3
Related Papers
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
|Haematologica|2019|215
A phase 2 study of vorinostat in acute myeloid leukemia
|Haematologica|2009|119